# REVIEWS OF THERAPEUTICS

# The Microbiome in Mental Health: Potential Contribution of Gut Microbiota in Disease and Pharmacotherapy Management

Stephanie A. Flowers,[1] and Vicki L. Ellingrod,[1,2,*]

[1]College of Pharmacy, Clinical Social and Administrative Sciences, University of Michigan, Ann Arbor, Michigan;
[2]Department of Psychiatry, School of Medicine, University of Michigan, Ann Arbor, Michigan

The gut microbiome is composed of ~$10^{13}$–$10^{14}$ microbial cells and viruses that exist in a symbiotic bidirectional communicative relationship with the host. Bacterial functions in the gut have an important role in healthy host metabolic function, and dysbiosis can contribute to the pathology of many medical conditions. Alterations in the relationship between gut microbiota and host have gained some attention in mental health because new evidence supports the association of gut bacteria to cognitive and emotional processes. Of interest, illnesses such as major depressive disorder are disproportionately prevalent in patients with gastrointestinal illnesses such as inflammatory bowel disease, which pathologically has been strongly linked to microbiome function. Not only is the microbiome associated with the disease itself, but it may also influence the effectiveness or adverse effects associated with pharmacologic agents used to treat these disorders. This field of study may also provide new insights on how dietary agents may help manage mental illness both directly as well as though their influence on the therapeutic and adverse effects of psychotropic agents.

KEY WORDS microbiome, drug metabolism, psychiatry, metagenomics.

The human microbiome is primarily composed of 10–100 trillion bacterial symbionts that are commensal to our gut, mucosal surfaces, and skin.[1] These microbes greatly outnumber our somatic and germ cells by ~10-fold.[1] Aside from variation in our genomic DNA, we understand that the collective genomic content of our gastrointestinal microbiome profiles also contributes to human diversity.[1, 2] Although the gut microbiome actually consists of a variety of microorganisms, such as commensal fungi, viruses, protozoa, and parasites, the vast majority of work focuses on bacterial colonizers and is the focus of this review. The bacterial component of gut microbiota is composed of more than 1000 phylotypes (organisms classified based on evolutionary relationships), predominantly obligate anaerobes, with *Firmicutes* and *Bacteroidetes* representing more than 90% of the total microbiota.[3] Gut microbiota structure and function (the metagenome) is influenced by a variety of factors including host physiology, diet, antimicrobial medications, infections, and environment.

Although microbiome research is still developing, a growing body of evidence also supports the effect of microorganisms on cognitive and emotional processes. This review summarizes the role of the microbiome on mental illness, focusing on the interaction of the microbiome and pharmacologic management of psychiatric disease.

## Microbiome in the Gut–Brain Axis

The *gut–brain axis* is a term that defines the bidirectional communication between an individual's microbiome and brain, and it has

---

*Address for correspondence: Vicki L. Ellingrod, College of Pharmacy, Clinical Social and Administrative Sciences, University of Michigan, 428 Church Street, Room #2053, Ann Arbor, MI 48109; e-mail: vellingr@med.umich.edu.

become a topic of interest in psychiatry and neuroscience. Communication between the gut and brain can occur by neural, hormonal, or immunologic mechanisms. The ubiquitous presence of neuroendocrine hormones in both mammalian and nonmammalian systems has been recognized for decades. Bacterially produced neuroactive compounds include catecholamines, such as norepinephrine and dopamine, $\gamma$-aminobutyric acid (GABA), histamine, serotonin, and acetylcholine, which have known roles in most mental illnesses as well as in the mechanisms of action of psychiatric drugs.[4] Remarkably, the complete identical biosynthetic pathway for catecholamines was found in bacteria, which led to the hypothesis that mammalian cell-to-cell signaling systems, such as neuroendocrine pathways, are derived from late horizontal gene transfer from bacteria.[5] Not only do certain species of endogenous bacteria produce these chemicals but some bacteria possess receptors to these neuroactive compounds, which suggests these compounds not only facilitate interbacterial communication but also mediate communication from the host.[6] This intersection of neurobiology and microbiology has been termed *microbial endocrinology.*

Gut–brain communication can be mediated in part through enteric, vagal, and central nervous pathways.[7] The enteric nervous system (ENS) is embedded into the lining of the intestinal tract from the esophagus to the colon and governs the function of the gastrointestinal system. Despite considerable innervation from the autonomic nervous system, the ENS operates largely independently of the central nervous system (CNS) and is sometimes referred to as the "second brain."[7] Neurochemicals produced by gut microbiota from the food we eat can directly interact with receptors found on components of the ENS and can influence the brain via ENS-CNS communication through the various pathways.[8]

The microbiome plays a critical part in the development of the immune response of the intestinal endothelium and the blood–brain barrier (BBB) system, as shown by work in germ-free mice. Compared with their conventionally housed counterpart, germ-free mice have stunted development of gut-associated lymphoid tissue, which is critical in pathogen recognition.[9] Germ-free mice have also exhibited increased BBB permeability compared with conventionally raised mice.[10] Intestinal and BBB integrity can be restored when germ-free mice are colonized with intestinal microflora. Psychiatric disorders have been linked to the immune system, and an emerging concept is that gut bacteria may be able to influence the emotional state of the host.[11] It is thought that a commonality between psychiatric illness and the gut may reside in inflammatory pathways. Indeed, high rates of comorbid depression have been found in patients with inflammatory disease states such as inflammatory bowel disease and rheumatoid arthritis.[12, 13]

## Understanding the Gut-to-Brain Connection Through Lipids

Short-chain fatty acids (SCFAs) are the major metabolic products of intestinal bacteria derived from the fermentation of carbohydrates and proteins in the gut.[14] The main SCFAs produced in the gut are acetic acid, propionic acid, and butyric acid, which come from dietary intake.[15] SCFAs interact with the human body by a number of different mechanisms including mediation of colonic epithelial cell growth, hepatic control of lipids and carbohydrates, gene expression, and energy sources for a wide array of tissues. Both propionic acid and butyric acid have been shown to be ligands for receptors involved in host energy homeostasis and inflammatory responses.[16] SCFAs can cross the BBB and might be environmental factors that contribute to neurodevelopment disorders such as autism spectrum disorders.[17] Recent work has highlighted the role of SCFAs and their regulation of immune responses by their effects on T cells, neutrophils, and colonocytes. Importantly, SCFAs have been shown to induce both effector and interleukin-10 T-regulatory cells, depending on the cytokine condition and immunologic context.[18, 19]

Bile acids are not only a known contributor to drug pharmacokinetics but are also a regulator of gut microbiome composition.[20] Formed in the liver, bile acids account for most of the cholesterol turnover in the body. Bile acids form micelles in bile and are excreted in the small intestine after eating, where they are an essential component required for the absorption of lipophilic vitamins, fat, and drugs. The gut microbiome is capable of producing secondary bile acids such as deoxycholic acid and lithocholic acid that affect host metabolic processes, drug metabolism, and immune response.[21, 22] Bile acids mediate these processes through the activation of receptors such as the farnesoid X, pregnane X, vitamin D (VDR), and TGR5 receptors.[23, 24] Activation of

the VDR exhibits a wide range of immunomodulatory effects, and VDR ligands have been shown to reduce messenger RNA (mRNA) expression and decrease plasma concentrations of proinflammatory cytokines.[24–26] Bile acids also have antimicrobial properties despite the microbiome's critical role in their biotransformation; thus, a dynamic equilibrium exists between the microbiome and the bile acid pool.[27]

## Cometabolism of Drugs by Host and Gut Bacteria

The pharmacokinetics of orally administered drugs can be complicated and depend on measures such as the chemical properties and environmental risk parameters specific for each drug. Knowledge of how human genetics affect drug pharmacokinetics and pharmacodynamics has further advanced our understanding of interindividual variations in drug efficacy and adverse effects, but much variation remains unexplained. An important but sometimes overlooked contributor to drug metabolism is the gut microbiota, which expands the metabolic processes of these compounds beyond that of mammalian-encoded enzymes.

Microbiome-mediated reactions in the gut tend to be dominated by reduction or hydrolysis reactions, whereas mammalian metabolism shows a greater propensity for oxidation and conjugation.[28] Gut microbiota have been shown to participate in the reductive metabolism of psychotropic medications such as the benzodiazepine clonazepam.[29] Risperidone, an atypical antipsychotic, has been shown in postmortem studies to undergo gut-mediated isoxazole scission.[30] In addition, studies with levodopa, a mainstay in the treatment for Parkinson disease, show that the presence of *Helicobacter pylori* is associated with decreased plasma levels of the drug.[31] Although the pharmacokinetics of these medications may, in part, be altered by the microbiome, there are currently no defined clinical consequences of these occurrences. The gut microbiota can also indirectly contribute to xenobiotic metabolism by altering gene expression of hepatic enzymes that aid in the metabolism and detoxification of drugs outside of the gut. Studies in colonized and germ-free rats (rats cultivated with no intestinal microbiota) showed that the microbiome affects hepatic concentration of both phase I and phase II metabolizing enzymes, which are responsible for transformation of most prescribed medications.[32, 33]

## Microbiome, Inflammation, and Mood

Changes in proinflammatory and cell-mediated immune cytokines have been thoroughly documented in psychiatric diseases such as major depressive disorder (MDD). In fact, in addition to genetic and environmental factors, a robust association has been defined for MDD, immune response, and inflammation.[34, 35] Evidence suggests that antidepressants, such as the tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs), may function to normalize cytokine levels, and this may be an additional therapeutic mechanism secondary to their effect on neurotransmitters.[34, 36] Several studies have examined the effects of antidepressants on bacterial endotoxin lipopolysaccharide (LPS)-induced inflammation and depressive symptoms in animals. In rodents, pretreatment with SSRIs (fluoxetine or paroxetine) or serotonin-norepinephrine reuptake inhibitors (venlafaxine and duloxetine) reduced LPS-induced inflammation and depressive-like behaviors.[37]

Few studies have examined whether an increased gastrointestinal permeability with an increased translocation of LPS from gram-negative bacteria may play a role in the pathophysiology of MDD and other mental illnesses. One study in humans examined levels of serum antibodies against LPS of gram-negative enterobacteria and found higher levels in patients with MDD than in controls.[38] Alterations in gut epithelial permeability in patients with autism and schizophrenia has been described but without conclusive results.[39] In animals, acute and chronic stress has been shown to lead to increased gut permeability and bacterial translocation.[40, 41] In these studies, the therapeutic benefits, such as reduced stress-induced corticosterone level, anxiety, and depression-related behaviors were obtained through the administration of probiotics. The therapeutic benefits of adjunct therapy with minocycline and doxycycline have been explored in both animal and human studies for MDD and schizophrenia.[42–44] Minocycline has antioxidant, anti-inflammatory, and neuroprotective properties that are not related to its antimicrobial properties but mirror many of the deficits observed in MDD.[45, 46]

## Microbiome, Obesity, and Cardiovascular Disease in the Mental Health Population

Longitudinal studies following the introduction of atypical antipsychotics (AAPs) have noted the growing contribution of cardiac and

metabolic disease to increased mortality in subjects with schizophrenia.[47] Data suggest that the standardized mortality ratio for cardiac disease in these subjects is increasing compared with the general population.[48, 49] Due to the wealth of data that links changes in the microbiome to obesity and metabolic syndrome, the role of the microbiome in AAP-associated metabolic risk is currently being investigated in animal models.

A study of olanzapine use in rats demonstrated that treatment had significant effects on a number of physiologic, inflammatory, and microbial parameters and that many, but not all, were more pronounced in females compared with males.[50] Specific microbiome alterations in olanzapine-treated female rats included dose-dependent increased levels of *Firmicutes*, decreased levels of *Bacteroidetes* species, and overall decreased biodiversity. These observations were replicated in male rats but only at higher doses. In a follow-up study performed in female rats, coadministration of antibiotics attenuated the physiologic and inflammatory effects of olanzapine use.[51] A study in germ-free mice determined that gut bacteria were not only necessary but sufficient for olanzapine-mediated weight gain.[52] As seen in previous studies, colonized mice treated with olanzapine showed a shift in gut microbiota toward an "obesogenic bacterial profile."[53] Finally, in an in vitro model, olanzapine was determined to have antimicrobial activity against enteric bacterial strains.[52] In all, these studies make a strong case for the translation of these types of studies to humans.

## Personalized Management of Gut Microbiota

Currently, interest in exploring probiotics as a component of nutrition-based health is widespread. Probiotics are currently defined as a dietary supplement containing live bacterial cultures that is taken orally in adequate quantities to exert a health benefit. Although many bacteria are advertised as probiotics, data show that the in vivo effects of different species vary greatly, and few have been thoroughly investigated. Derived benefits from probiotic microorganisms are due to a number of different actions including conferring protection against pathogenic organisms and modulation of the immune response, and the actions of microbial-derived metabolic products.[54] Evidence that using probiotics to affect human behavior is limited, but there are data that support its use as an adjuvant treatment in mental health.

One report[55] assessed the potential benefits of the probiotic *Bifidobacterium infantis* compared with the SSRI citalopram on mood using a rat maternal separation model. In this study, maternally separated rats were chronically treated with *B. infantis* or citalopram. Assessments made were motivational state, as measured by a forced swim test, cytokine concentrations in whole blood samples, monoamine levels in the brain, and central and peripheral hypothalamic-pituitary-adrenal axis measures. For nontreated rats, maternal separation reduced swim behavior (indicating a depressed-like behavior) and decreased mobility as demonstrated by the forced swim test. Decreased norepinephrine levels were measured in the brain in addition to greater proinflammatory cytokine and amygdala corticotropin-releasing factor mRNA levels. Probiotic treatment resulted in improvement of mood deficiencies in addition to normalization of cytokine levels and basal norepinephrine levels, which was comparable to the effects of citalopram.

Another study[41] investigated the impact of *Lactobacillus rhamnosus* on behavior and central GABA receptors in mice. Probiotic-treated mice exhibited reduced anxiety symptoms and altered cerebral expression of both GABA type A and GABA type B receptors compared with mice treated with inactive broth. A subset of animals underwent a vagotomy and was treated with either the probiotic or inactive broth. Vagotimized mice treated with a probiotic did not show a decrease in anxiety, indicating that the vagus may mediate behavioral and neurochemical effects of *L. rhamnosus*.

Table 1 provides a summary of preclinical and clinical studies examining microbiomes in animals or humans with behavioral and psychological disorders.

## Perspective and Future: Impact of Host Microbiome on Personalized Medicine

Advances in next-generation sequencing and culture-independent approaches to study the microbiome have led to a new understanding of the microbiome's involvement on host physiology and disease. The most common method of studying microbiome biodiversity and structure is by sequencing hypervariable regions of the gene encoding the small ribosomal subunit known as 16S.[67] Because many of the anaerobic species that inhabit the gut are not culturable, we may find that composition data may not be

**Table 1. Preclinical and Clinical Studies Examining Microbiomes in Animals or Humans with Behavioral and Psychological Disorders**

| Model | Probiotic intervention or other method | Conclusions |
|---|---|---|
| Preclinical studies | | |
| Germ free | | |
| Mouse (female)[56] | Comparison of germ-free vs SPF mice | Basal behavior for germ-free mice vs SPF mice was interpreted as anxiolytic; increased BDNF mRNA in hippocampus of germ-free animals |
| Mouse[57] | *Campylobacter jejuni* | Increased anxiety-like behavior and increased markers of activation within the limbic structures in the brain |
| Mouse[41] | *Lactobacillus rhamnosus* | Induced region-dependent alterations in GABA mRNA in the brain and reduced stress-induced corticosterone level and anxiety- and depression-related behavior that was not seen in vagotimized mice |
| Mouse[58] | *Lactobacillus acidophilus* L36 or *Lactobacillus salivarius* L38 | L36 increased the expression of Th2 cytokines (IL-5, IL-6 and TGF-β1) and Th17 (IL-17a, TNF-α and IL-6) inflammatory response |
| Conventional | | |
| Rat[59] | *Lactobacillus helveticus* and *Lactobacillus rhamnosus* | Intervention prevented chronic stress-induced intestinal abnormalities |
| Rat[55] | *Bifidobacterium infantis* | Decreased depressive-like behavior in maternal separation model |
| Rat (female)[60] | *Lactobacillus farciminis* | Treatment attenuated the HPA response to acute stress |
| Clinical studies | | |
| Human (female)[61] | FMPP; *Bifidobacterium animalis*, *Streptococcus thermophiles*, *Lactobacillus bulgaricus*, and *Lactococcus lacti* | Intervention affected activity of brain regions that control central processing of emotion and sensation |
| Human[62] | *Lactobacillus casei* | Improved mood |
| Human and rat[63] | *Lactobacillus helveticus* and *Bifidobacterium longum* | Beneficial effects on anxiety and depression and showed reduced urinary levels of cortisol |
| Human[64] | Prebiotics | Intervention associated with lower cortisol levels at awakening and improved attention to positive stimuli compared with negative stimuli in an emotional categorization task and in an emotional recognition task |
| Human[65] | *Lactobacillus casei* | Decreased anxiety in patients with chronic fatigue syndrome |
| Humans with schizophrenia[66] | *Lactobacillus rhamnosus* GG and *Bifidobacterium lactis* Bb12. | 14 weeks of probiotic add-on treatment significantly reduced levels of vWF and increased levels of MCP-1, BDNF, RANTES, and MIP-1 beta with borderline significance (p= 0.08) |

BDNF = brain-derived neurotrophic factor; FMPP = fermented milk product with probiotic; GABA = γ-aminobutyric acid; HPA = hypothalamic-pituitary-adrenal; IL = interleukin; MCP-1 = monocyte chemotactic protein-1; MIP-1 = macrophage inflammatory protein-1; mRNA = messenger RNA; prebiotics = oligosaccharides that can promote growth of beneficial commensal bacteria; RANTES = a cytokine that is a member of the IL-8 superfamily of cytokines; SPF = specific pathogen free; TGF = transforming growth factor; Th = T helper; TNF-α = tumor necrosis factor α; vWF = von Willebrand factor.

sufficient to define the role of the microbiome in health and disease. Perhaps even more insightful, culture-independent methods such as shotgun sequencing of the metagenome are now used to study both the composition and the functionality of processes occurring in the gut.[68]

## Conclusion

Consideration of the human gut microbial composition and function will be a necessary part of future personalized medicine strategies. Great potential exists in examining the microbiome to develop diagnostic markers of disease and to take advantage of therapeutic strategies that will maximize the benefice of a healthy gut

structure. Most data describing the importance of the microbiome in psychiatric illness and pharmacologic management are currently from ex vivo or animal preclinical models. Biologic validation of these methods on large human cohorts will be necessary to demonstrate the strength and clinical utility of these types of predictors and therapeutic management of disease.

## References

1. **Turnbaugh PJ, Ley RE, Hamady M, Fraser-Liggett C, Knight R, Gordon JI.** The human microbiome project: exploring the microbial part of ourselves in a changing world. Nature 2007;449(7164):804–10.
2. **Hugenholtz P, Tyson GW.** Microbiology metagenomics. Nature 2008;455:481–3.

3. **Maurice CF, Haiser HJ, Turnbaugh PJ.** Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 2013;2:39–50.

4. **Roshchina VV.** Evolutionary considerations of neurotransmitters in microbial, plant, and animal cells. In: Lyte M, Freestone PPE, eds. Microbial Endocrinology: Interkingdom Signaling in Infectious Disease and Health. New York, Dordrecht, Heidelberg, London: Springer Science+Business Media, 2010:17–52.

5. **Iyer LM, Aravind L, Coon SL, Klein DC, Koonin EV.** Evolution of cell-cell signaling in animals: did late horizontal gene transfer from bacteria have a role? Trends Genet 2004;20 (7):292–9.

6. **Guthrie GD, Nicholson-Guthrie CS, Leary HL.** A bacterial high-affinity GABA binding protein: isolation and characterization. Biochem Biophys Res Commun 2000;268(1):65–8.

7. **Kabouridis PS, Pachnis V.** Emerging roles of gut microbiota and the immune system in the development of the enteric nervous system. J Clin Invest 2015;125(3):956–64.

8. **Zhou L, Foster JA.** Psychobiotics and the gut-brain axis: in the pursuit of happiness. Neuropsychiatr Dis Treat 2015;11:715–23.

9. **Min YW, Rhee P-L.** The role of microbiota on the gut immunology. Clin Ther 2015;37(5):968–75. doi: 10.1016/j.clinthera.2015.03.009.

10. **Braniste V, Al-Asmakh M, Kowa C, et al.** The gut microbiota influences the blood brain barrier permeability in mice. Sci Transl Med 2014;6(263):263ra158.

11. **Severance EG, Yolken RH, Eaton WW.** Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr Res 2014. DOI: http://dx.doi.org/10.1016/j.schres.2014.06.027.

12. **Lydiard RB.** Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry 2001;62(Suppl 8):38–45; discussion 46–7.

13. **Matcham F, Rayner L, Steer S, Hotopf M.** The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013;52(12):2136–48.

14. **Macfarlane GT, Macfarlane S.** Bacteria, colonic fermentation, and gastrointestinal health. J AOAC Int 2012;95(1):50–60.

15. **Cummings JH.** Short chain fatty acids in the human colon. Gut 1981;22(9):763–79.

16. **Donohoe DR, Garge N, Zhang X, Sun W, O'Connell TM, Bunger MK, Bultman SJ The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon.** Cell Metab 2011;13(5):517–26.

17. **De Theije CGM, Wopereis H, Ramadan M, et al.** Altered gut microbiota and activity in a murine model of autism spectrum disorders. Brain Behav Immun 2014;37:197–206.

18. **Smith PM, Howitt MR, Panikov N, et al.** The microbial metabolites, short chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013;341:6145.

19. **Park J, Kim M, Kang SG, Jannasch AH, Cooper B, Patterson J, Kim CH Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway.** Nature 2015;8:80–93.

20. **Li T, Chiang JYL.** Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev 2014;66(4):948–83.

21. **Allen K, Jaeschke H, Copple BL.** Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011;178(1):175–86.

22. **Nguyen A, Bouscarel B.** Bile acids and signal transduction: role in glucose homeostasis. Cell Signal 2008;20(12):2180–97.

23. **Kawamata Y, Fujii R, Hosoya M, et al.** A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003;278 (11):9435–40.

24. **Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K.** Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008;7(8):678–93.

25. **Cantorna MT, Waddell A.** The vitamin D receptor turns off chronically activated T cells. Ann N Y Acad Sci 2014;1317:70–7525.

26. **Ogura M, Nishida S, Ishizawa M, et al.** Vitamin D3 modulates the expression of bile acid regulatory genes and represses inflammation in bile duct-ligated mice. J Pharmacol Exp Ther 2009;328(2):564–70.

27. **Hofmann AF, Eckmann L.** How bile acids confer gut mucosal protection against bacteria. Proc Natl Acad Sci U S A 2006;103 (12):4333–4.

28. **Li H, Jia W.** Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity. Clin Pharmacol Ther [Internet]. 2013;94(5):574–81.

29. **Elmer GW, Remmel RP.** Role of the intestinal microflora in clonazepam metabolism in the rat. Xenobiotica 1984;14 (11):829–40.

30. **Taylor K, Elliott S.** An unusual case of risperidone instability in a fatality presenting an analytical and interpretative challenge. Drug Test Anal 2013;10:748–52.

31. **Fiddian-Green RG.** Helicobacter pylori eradication and L-dopa absorption in patients with PD and motor fluctuations. Neurology 2007;68(13):1085.

32. **Meinl W, Sczesny S, Brigelius-Flohé R, Blaut M, Glatt H.** Impact of gut microbiota on intestinal and hepatic levels of phase 2 xenobiotic-metabolizing enzymes in the rat. Drug Metab Dispos 2009;37(6):1179–86.

33. **Claus SP, Ellero SL, Berger B, et al.** Colonization-induced host-gut microbial metabolic interaction. MBio 2011;2(2):e00271–10.

34. **Noto C, Rizzo LB, Mansur RB, McIntyre RS, Maes M, Brietzke E.** Targeting the inflammatory pathway as a therapeutic tool for major depression. NeuroImmunoModulation 2014;21 (2–3):131–9.

35. **Leonard B, Maes M.** Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev 2012;36(2):764–85.

36. **Liu D, Wang Z, Liu S, Wang F, Zhao S, Hao A.** Anti-inflammatory effects of fluoxetine in lipopolysaccharide(LPS)-stimulated microglial cells. Neuropharmacology 2011;61(4):592–9.

37. **Ohgi Y, Futamura T, Kikuchi T, Hashimoto K.** Effects of antidepressants on alternations in serum cytokines and depressive-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 2013;103(4):853–9.

38. **Maes M, Kubera M, Leunis J-C.** The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29(1):117–24.

39. **Julio-Pieper M, Bravo JA, Aliaga E, Gotteland M.** Review article: intestinal barrier dysfunction and central nervous system disorders—a controversial association. Aliment Pharmacol Ther 2014;40(10):1187–201.

40. **Ait-Belgnaoui A, Bradesi S, Fioramonti J, Theodorou V, Bueno L.** Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005;113(1–2):141–7.

41. **Bravo JA, Forsythe P, Chew MV, et al.** Ingestion of *Lactobacillus* strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci U S A 2011;108(38):16050–5.

42. **Oya K, Kishi T, Iwata N.** Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 2014;29(5):483–91.

43. **Dean OM, Maes M, Ashton M, et al.** Protocol and rationale—the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial. Clin Psychopharmacol Neurosci 2014;12 (3):180–8.

44. **Mello BSF, Monte AS, McIntyre RS, et al.** Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res 2013;47(10):1521–9.

45. **Morimoto N, Shimazawa M, Yamashima T, Nagai H, Hara H.** Minocycline inhibits oxidative stress and decreases in vitro and in vivo ischemic neuronal damage. Brain Res 2005;1044 (1):8–15.

46. Homsi S, Federico F, Croci N, et al. Minocycline effects on cerebral edema: relations with inflammatory and oxidative stress markers following traumatic brain injury in mice. Brain Res 2009;1291:122–32.

47. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80 (1):19–32.

48. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study. BMJ 2000;321(7259):483–4.

49. Hansen V, Jacobsen BK, Arnesen E. Cause-specific mortality in psychiatric patients after deinstitutionalisation. Br J Psychiatry 2001;179:438–43.

50. Davey KJ, O'Mahony SM, Schellekens H, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology 2012;221(1):155–69.

51. Davey KJ, Cotter PD, O'Sullivan O, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry 2013;3:e309.

52. Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444 (7122):1022–3.

53. Morgan AP, Crowley JJ, Nonneman RJ, et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS ONE 2014;9(12):e115225.

54. Sanders ME, Lenoir-Wijnkoop I, Salminen S, et al. Probiotics and prebiotics: prospects for public health and nutritional recommendations. Ann N Y Acad Sci 2014;1309:19–29.

55. Desbonnet L, Garrett L, Clarke G, Kiely B, Cryan JF, Dinan TG. Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression. Neuroscience 2010;170(4):1179–88.

56. Neufeld KM, Kang N, Bienenstock J, Foster JA. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil 2011;23(3):255–64.

57. Goehler LE, Park SM, Opitz N, Lyte M, Gaykema RP. Campylobacter jejuni infection increases anxiety-like behavior in the holeboard: possible anatomical substrates for viscerosensory modulation of exploratory behavior. Brain Behav Immun 2008;22(3):354–66.

58. Steinberg R, Lima M, Gomes de Oliveira NL, et al. Effect of intestinal colonization by two Lactobacillus strains on the immune response of gnotobiotic mice. Benef Microbes 2014;5 (4):409–19.

59. Zareie M, Johnson-Henry K, Jury J, et al. Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006;55 (11):1553–60.

60. Ait-Belgnaoui A, Durand H, Cartier C, et al. Prevention of gut leakiness by a probiotic treatment leads to attenuated HPA response to an acute psychological stress in rats. Psychoneuroendocrinology 2012;37:1885–95.

61. Tillisch K, Labus J, Kilpatrick L, et al. Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology 2013;144(7):1394–401, 1401.e1-4.

62. Benton D, Williams C, Brown A. Impact of consuming a milk drink containing a probiotic on mood and cognition. Eur J Clin Nutr 2007;61(3):355–61.

63. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. Br J Nutr 2011;105(5):755–64.

64. Schmidt K, Cowen PJ, Harmer CJ, Tzortzis G, Errington S, Burnet PW. Prebiotic intake reduces the waking cortisol response and alters emotional bias in healthy volunteers. Psychopharmacology 2015;232(10):1793–801.

65. Rao AV, Bested AC, Beaulne TM, et al. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut Pathog 2009;1(1):6.

66. Tomasik J, Yolken RH, Bahn S, Dickerson FB. Immunomodulatory effects of probiotic supplementation in schizophrenia patients: a randomized, placebo-controlled trial. Biomark Insights 2015;10:47–54.

67. Schloss PD, Handelsman J. Status of the microbial census. Microbiol Mol Biol Rev 2004;68(4):686–91.

68. Abram F. Systems-based approaches to unravel multi-species microbial community functioning. Comput Struct Biotechnol J 2014;13:24–32.